Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Changes in the lymph node microenvironment induced by oncostatin M.

Isabelle Louis1, Gaël Dulude, Sophie Corneau

  • 1Guy-Bernier Research Center, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada.

Blood
|April 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PCSK9 expression in human atherosclerotic lesions and vascular smooth muscle cells.

Atherosclerosis·2026
Same author

Noncanonical Transcription and Splicing Shape the Colorectal Cancer Immunopeptidome in MSI and MSS Tumors.

Molecular & cellular proteomics : MCP·2026
Same author

The orphan nuclear receptor NR4A3 is dispensable for resident memory CD8+ T-cell generation.

ImmunoHorizons·2026
Same author

CDK4/6 inhibition reprograms the breast cancer immunopeptidome via Rb-dependent chromatin and transcriptomic remodeling.

Cell reports·2025
Same author

A large French family with TGFBR2 pathogenic variant: illustration of variability.

Orphanet journal of rare diseases·2025
Same author

CD33 epitope editing unlocks UM171-expanded cord blood grafts for AML immunotherapy.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Oncostatin M (OM) enhances T-cell development in lymph nodes via cyclooxygenase-2 (COX-2) and high endothelial venules (HEVs). CCL20 chemokine drives memory CD4 T-cell expansion, offering targets for immune therapies.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cell Biology

Background:

  • Oncostatin M (OM) transforms lymph nodes (LNs) into potent immune sites.
  • This transformation involves thymus-independent T-cell development and memory T-cell pool expansion.

Purpose of the Study:

  • To elucidate the mechanisms regulating T-cell development in OM-transformed LNs.
  • To identify molecular targets for enhancing T-cell populations.

Main Methods:

  • Investigated cyclooxygenase-2 (COX-2)-dependent neoangiogenesis in LckOM LNs.
  • Analyzed the role of high endothelial venules (HEVs) and OM-receptor beta-chain.
  • Examined the impact of CCL20 chemokine on CD4 T-cell proliferation.

Main Results:

Related Experiment Videos

  • T-cell development in LckOM LNs is regulated by COX-2-dependent neoangiogenesis involving HEVs.
  • LN HEVs express high levels of OM-receptor beta-chain, localizing extrathymic T-cell development.
  • CCL20 chemokine produced by LN stromal cells drives memory phenotype CD4 T-cell pool expansion.
  • CCL20/CCR6 interactions increase proliferation of CD62L(lo) CD4 T cells.

Conclusions:

  • LN HEVs are potential targets for creating thymic substitutes.
  • CCL20 is identified as the first molecule to increase memory phenotype CD4 T-cell proliferation.
  • Findings suggest therapeutic strategies for expanding the CD4 memory T-cell compartment.